JPM24: ‘Diabesity’ duopoly between Novo, Lilly takes center stage

JPM24: ‘Diabesity’ duopoly between Novo, Lilly takes center stage

Submitted by admin on January 11, 2024 - 11:18am
Source: 
Medical Marketing and Media
News Tags: 
JPMHC 2024
obesity
diabetes
diabesity
Novo Nordisk
Eli Lilly
Headline: 
JPM24: ‘Diabesity’ duopoly between Novo, Lilly takes center stage
snippet: 

The CEOs of Eli Lilly and Novo Nordisk — rivals in the GLP-1 obesity market — addressed nagging questions at the 2024 J.P. Morgan Healthcare Conference.

Do Not Allow Advertisers to Use My Personal information